The National Drug Abuse Clinical Trials Network: New England Consortium Node

国家药物滥用临床试验网络：新英格兰联盟节点

• 批准号: 10442107
• 负责人: Gail D'Onofrio
• 金额: $ 9.16万
• 依托单位: YALE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-07-01 至 2022-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10442107
• 关键词: Administrative Supplement; Clinical Trials Network; Cocaine Users; Data Analyses; Drug abuse; Enrollment; Ethnic Origin; Hispanics; Latinx; Meta-Analysis; National Institute of Drug Abuse; New England; Outcome; Race; Randomized; Registries; Research Personnel; Substance Use Disorder; Time; Treatment outcome; comparative effectiveness; psychosocial; sex; substance user; success

ABSTRACT This Administrative Supplement to the NIDA Clinical Trials Network: New England Consortium Node is to support three specific concepts: 1) Comprehensive Meta-Analysis of CTN Treatment Outcomes by Race and Sex This project will perform additional meta-analyses examining whether/how race and sex interact to predict likelihood of treatment success and likelihood of randomization into a CTN trial versus screen fail. Exploratory analysis will be conducted evaluating how these outcomes vary by ethnicity (i.e. Hispanic/Latinx). 2) Using Integrative Data Analysis to Examine the Impact of Psychosocial Treatments for Black Cocaine Users Enrolled in the CTN Using integrative data analysis of multiple CTN trials, this project will examine comparative effectiveness and moderators of substance use disorder treatments for Black substance users. 3) NIDA CTN Substance Use Disorder (SUD) Registry Initiative concept This project will establish a NIDA CTN Substance Use Disorder Registry to allow investigators to follow substance users over time.

摘要 NIDA临床试验网络的行政副刊：新英格兰协会 节点支持三个具体概念： 1)不同种族、性别CTN治疗结果的综合Meta分析 该项目将进行额外的荟萃分析，考察种族和性别是否/如何 相互作用以预测治疗成功的可能性和随机进入 CTN试验与筛选失败。将进行探索性分析，评估这些 结果因族裔而异(即西班牙裔/拉丁裔)。 2)运用综合数据分析方法考察心理社会的影响 参加CTN的黑可卡因使用者的治疗 使用多个CTN试验的综合数据分析，该项目将检查 物质使用障碍治疗的比较有效性和调节剂 黑色物质使用者。 3)NIDA CTN物质使用障碍(SUD)登记倡议概念 该项目将建立一个NIDA CTN物质使用障碍登记处，以允许 调查人员跟踪药物使用者一段时间。